EU OKs Raptor's marketing application for cystinosis drug Procysbi

09/13/2013 | American City Business Journals

The European Commission approved Raptor Pharmaceutical's application to market its nephropathic cystinosis drug Procysbi in the European Union. The drugmaker must obtain approval from each country. Raptor CEO Chris Starr said the action "brings us a major step closer to providing access to this important new therapeutic option to cystinosis patients in Europe."

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR